Resolutions from CellaVision AB:s (publ), 556500-0998, Annual General Meeting (AGM) on April 23, 2008

The Annual General Meeting resolved as follows:

To adopt the Statement of Income and Balance Sheet for the parent
company and the Group for the year 2007.
 
That net profit for the year, SEK 4,433,981, be carried forward to
new account.
 
To discharge the Board of Directors and the Chief Executive Officer
from liability. 
 
That the Board of Directors shall consist of five regular members and
no alternatives. 
 
To re-elect the following Directors: Niels Freiesleben, Christer
Fåhraeus, Lars Gatenbeck, Sven-Åke Henningsson, Torbjörn Kronander 
 
To elect Lars Gatenbeck as the Chairman of the Board. 
 
That the remuneration to the Chairman of the Board shall amount to
SEK 140,000 (140,000). The remuneration to other directors shall
amount to SEK 70,000 (70,000) each, in total SEK 280,000 (280,000).
Remuneration to the auditors shall be paid on a current account
basis.
 
To approve the Board of Directors' recommendation to resolve to issue
a maximum of 3,000,000 shares. If the authorization is fully
implemented, there will be a maximum of 11.2 percent dilution of
share capital. The General Annual Meeting's complete decisions as
accounted for above are available at the company address, Ideon
Science Park in Lund, and are sent to those share holders who request
it.
 
Lund April 23, 2008
 
CellaVision AB (publ)
Board of Directors
 
 
CEO Yvonne Mårtensson's address to the meeting will be available in
Swedish at www.cellavision.com.
 
 
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB. Tel: 070 535
44 44. E-mail: lars.gatenbeck@gzgroup.se
Yvonne Mårtensson, CEO, CellaVision AB. Tel: 0708 33 77 82. E-mail:
yvonne.martensson@cellavision.com
 
 
About CellaVision
CellaVision AB develops, markets, and sells the market leading  image
analysis based systems for routine  analysis of blood and other  body
fluids. The company has a core competence in development of  software
for  automatic  image  analysis  of   cells  and  cell  changes   for
applications in health  and medical  care. The  company develops  and
markets systems for automatic differentials of white blood cells  and
red morphology, and software for  education and quality assurance  of
differentials. The company's  associates have  expertise in  advanced
imaging analysis, artificial intelligence, and automated microscopy.
 
The company headquarters are in Lund, Sweden and has subsidiaries  in
Jupiter, FL, USA, Toronto, ON,  Canada and Yokohama, Japan. For  more
information, visit www.cellavision.com.
 
CellaVision's share is  listed on  First North at  the OMX  Stockholm
Stock Exchange. The company's Certified Advisor is Remium AB.